European Archives - Page 207 of 1060 - European Medical Journal

Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Interruption in Hepatitis B Virus/HIV Co-Infected Individuals

Among hepatitis B virus (HBV) core antibody positive (cAb+) people with HIV, suppressive HBV treatment, including either tenofovir…

Barriers and Motivators for Implementation of Lifestyle Changes in Metabolic Dysfunction-Associated Steatotic Liver Disease

Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) experience difficulties in complying with required lifestyle…

TGR5 Deficiency in Liver Sinusoidal Endothelial Cells Disrupts Angiocrine Signalling After Hepatectomy

Bile acid (BA) receptors like farnesoid X receptor (FXR) and TGR5 have been implicated in liver regeneration.

EASL 2024 Abstract Highlights

The following highlights spotlight the latest research in hepatology, featuring studies presented at this year’s EASL Congress….

Roche's obesity drug shows promising results at Phase I

Another obesity drug could be on its way to the market after Roche announces positive results for its drug in a phase I trial.

MRI Scans Predict Atrophy in Parkinson’s Disease

Researchers have discovered that the progression of grey matter atrophy in the brain of patients with mild Parkinson’s disease can be predicted using MRI.

AI Model Bias in Diagnostic Medical Imaging

Researchers investigate the impact of demographic predictions on AI diagnostic fairness, revealing significant disparities for women and Black patients in chest X-ray screenings.

New Link Between Immunosuppressant Agents and Cancer in Kidney Transplant Recipients

Immunosuppression agent exposure is linked to an increased incidence of primary malignant neoplasms in kidney transplant recipients, and this association varies by age and sex.

SOHO 2024 Interview: Guillermo Garcia-Manero

One of the primary tasks of the President of SOHO is to prepare the Annual Meeting scheduled for the first week of September in Houston…

AZ’s Stefan Woxström on why without health, we don’t have anything

Stefan Woxström, Senior Vice President Europe and Canada, AstraZeneca, unpicks the current small molecule funding landscape, how to improve incentives to invest in rare diseases and more.